De Burlo Group’s Neurocrine Biosciences NBIX Stock Holding History

De Burlo Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$615K	Hold	4,667	–	–	0.14%	64
2025 Q4	$662K	Sell	4,667 -100	-2%	-$14.5K	0.08%	64
2025 Q3	$669K	Buy	4,767 +100	+2%	+$13.6K	0.08%	62
2025 Q2	$587K	Sell	4,667 -50	-1%	-$5.73K	0.08%	65
2025 Q1	$522K	Buy	4,717 +100	+2%	+$12.7K	0.08%	66
2024 Q4	$630K	Sell	4,617 -500	-10%	-$61.8K	0.08%	64
2024 Q3	$590K	Hold	5,117	–	–	0.07%	66
2024 Q2	$704K	Sell	5,117 -50	-1%	-$6.86K	0.09%	62
2024 Q1	$713K	Sell	5,167 -4,000	-44%	-$546K	0.09%	65
2023 Q4	$1.03M	Hold	9,167	–	–	0.18%	56
2023 Q3	$1.03M	Hold	9,167	–	–	0.18%	56
2023 Q2	$864K	Hold	9,167	–	–	0.14%	66
2023 Q1	$928K	Hold	9,167	–	–	0.18%	66
2022 Q4	$1.09M	Hold	9,167	–	–	0.24%	56
2022 Q3	$974K	Buy	+9,167	New	+$930K	0.23%	54
2022 Q2	–	Sell	-9,333	Closed	-$875K	–	160
2022 Q1	$875K	Sell	9,333 -1,450	-13%	-$123K	0.16%	62
2021 Q4	$918K	Sell	10,783 -700	-6%	-$64.4K	0.13%	74
2021 Q3	$1.1M	Hold	11,483	–	–	0.18%	67
2021 Q2	$1.12M	Hold	11,483	–	–	0.18%	62
2021 Q1	$1.12M	Sell	11,483 -100	-0.9%	-$10.5K	0.2%	61
2020 Q4	$1.11M	Sell	11,583 -300	-3%	-$29K	0.18%	59
2020 Q3	$1.14M	Buy	11,883 +133	+1%	+$15.4K	0.21%	59
2020 Q2	$1.02M	Hold	11,750	–	–	0.29%	42
2020 Q1	$1.02M	Sell	11,750 -300	-2%	-$29.4K	0.29%	42
2019 Q4	$1.29M	Sell	12,050 -300	-2%	-$31.4K	0.26%	56
2019 Q3	$1.11M	Hold	12,350	–	–	0.25%	54
2019 Q2	$1.04M	Sell	12,350 -300	-2%	-$24.6K	0.2%	59
2019 Q1	$1.11M	Sell	12,650 -3,650	-22%	-$305K	0.22%	67
2018 Q4	$1.16M	Sell	16,300 -600	-4%	-$57.5K	0.26%	61
2018 Q3	$2.08M	Hold	16,900	–	–	0.39%	68
2018 Q2	$1.66M	Hold	16,900	–	–	0.35%	65
2018 Q1	$1.4M	Hold	16,900	–	–	0.31%	64
2017 Q4	$1.31M	Sell	16,900 -800	-5%	-$54.6K	0.27%	68
2017 Q3	$1.08M	Sell	17,700 -4,650	-21%	-$245K	0.24%	68
2017 Q2	$1.03M	Sell	22,350 -5,300	-19%	-$257K	0.23%	71
2017 Q1	$1.2M	Sell	27,650 -23,800	-46%	-$1.02M	0.26%	64
2016 Q4	$1.99M	Sell	51,450 -1,000	-2%	-$45.3K	0.48%	55
2016 Q3	$2.66M	Hold	52,450	–	–	0.74%	55
2016 Q2	$2.38M	Hold	52,450	–	–	0.58%	57
2016 Q1	$2.07M	Sell	52,450 -900	-2%	-$35.7K	0.6%	56
2015 Q4	$3.02M	Hold	53,350	–	–	0.71%	52
2015 Q3	$2.12M	Sell	53,350 -4,000	-7%	-$193K	0.5%	58
2015 Q2	$2.74M	Sell	57,350 -1,000	-2%	-$42.4K	0.57%	58
2015 Q1	$2.32M	Sell	58,350 -3,000	-5%	-$107K	0.46%	67
2014 Q4	$1.37M	Sell	61,350 -200	-0.3%	-$3.79K	0.28%	69
2014 Q3	$964K	Sell	61,550 -2,400	-4%	-$35.9K	0.21%	69
2014 Q2	$949K	Sell	63,950 -1,700	-3%	-$24K	0.21%	64
2014 Q1	$1.06M	Buy	65,650 +24,300	+59%	+$416K	0.25%	66
2013 Q4	$386K	Sell	41,350 -7,400	-15%	-$72.2K	0.09%	84
2013 Q3	$552K	Buy	+48,750	New	+$670K	0.15%	70

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

De Burlo Group's NBIX Position: Q1 2026 in Review

De Burlo Group held its Neurocrine Biosciences (NBIX) position steady in Q1 2026 at 4,667 shares worth $615K. The position accounts for 0.14% of the portfolio, ranked #64.

De Burlo Group first reported a position in NBIX in Q3 2013 and has held it in 50 quarters since. The position peaked at $3.02M in Q4 2015. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

De Burlo Group held 4,667 shares of Neurocrine Biosciences worth $615K as of Q1 2026.
De Burlo Group left its Neurocrine Biosciences share count unchanged in Q1 2026.
Neurocrine Biosciences made up 0.14% of De Burlo Group's portfolio in Q1 2026, its #64 holding.
De Burlo Group first reported a position in Neurocrine Biosciences in Q3 2013 and has held it in 50 quarters since.
De Burlo Group's Neurocrine Biosciences position peaked at $3.02M in Q4 2015.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on De Burlo Group's 13F filing for Q1 2026, filed 14 May 2026.